Provider review
Push Health
Direct-to-doctor GLP-1 access — no subscription, pay per visit + medication.
Medically reviewed by Dr. Jane Novak, MD, MPH (opens in a new tab) 6 min read Fact checked Editorial integrityUpdated Jul 15, 2026
- 3.90/5 rating
- From $75.00/mo
- 51 states
- 1 GLP-1
Medically reviewed by Dr. Jane Novak, MD, MPH on July 15, 2026
Rating breakdown
How this provider scored, per dimension
Editorial scores out of 5 — see our scoring rubric for the criteria behind each axis.
- Overall
- 3.9/5
- Pricing
- 4.5/5
- Patient experience
- 3.7/5
- Delivery speed
- 3.9/5
- Customer support
- 3.6/5
- Billing clarity
- 4.1/5

From
$75/mo
Medications
1
States
51
Rating
3.9/5
~6 hr· self-reported
We earn a commission if you sign up through this link. Editorial ranking is independent.
What we liked
- No monthly membership — pay $75 per doctor visit, medication ordered separately
- Best fit for patients who want minimal friction and self-directed titration
- Works with a wide network of independent US-licensed doctors
What gave us pause
- Less structured than Ro/Hims — no built-in follow-up cadence
- Support is thinner than app-driven providers
- Compounded-first; brand-name pathway is inconsistent
Reader reviews
Verified user experiences. Reviews are moderated before publishing — we strip personal info and reject spam.
No user reviews yet
Be the first to share your experience — consults, shipping, billing, support. The form below takes ~2 minutes.
Ready to try Push Health?
From $75.00/mo. Commission-funded, editorially independent.
Get started with Push Health People also ask
Common questions readers ask
- How much does Wegovy cost without insurance?
- List price runs ~$1,350/mo at retail. NovoCare Pharmacy cash-pay direct from Novo Nordisk is $499/mo for all dose strengths. The Wegovy Savings Offer caps copay at $0-$225/mo for commercially insured patients depending on coverage status (not a flat $225 for everyone). Full evidence-graded answer
- Does insurance cover Zepbound?
- Most commercial insurance plans cover Zepbound with prior authorization for adults with BMI ≥30 (or ≥27 + a weight-related comorbidity). Medicare Part D excludes anti-obesity drugs by federal law, so Medicare patients pay cash unless they qualify for Lilly Cares. Full evidence-graded answer
- Is Ozempic the same as Wegovy?
- Same active molecule (semaglutide), different FDA indications and maximum doses. Ozempic = type 2 diabetes, max 2 mg/week. Wegovy = chronic weight management, max 2.4 mg/week. Insurance pathways are very different. Full evidence-graded answer
- Can I still get compounded GLP-1 in 2026?
- For semaglutide: no — FDA declared the shortage resolved February 21, 2025 and 503A compounding is no longer broadly permitted. For tirzepatide: shortage resolved October 2024 (re-affirmed December 2024), with a wind-down enforcement window that ended in 2025. Some clinics still market "compounded" formulations with added ingredients (B12, glycine) as personalized prescriptions; the legal status is contested. Full evidence-graded answer
- How does Wegovy compare to Saxenda?
- Both are GLP-1 agonists from Novo Nordisk. Wegovy (semaglutide, weekly) produces ~15% mean weight loss; Saxenda (liraglutide, daily) produces ~6-8%. Wegovy is also cheaper per kg-lost, more convenient, and has cardiovascular outcome data (SELECT trial). Saxenda was first approved for adolescents (2020); Wegovy followed in 2022 — both are available for ages 12-17. Full evidence-graded answer
Was this page helpful?